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Introduction {#rcr2428-sec-0001}
============

Non‐tuberculous mycobacteria (NTM) are ubiquitous in the environment and can cause various infectious diseases in humans. The prevalence of NTM‐induced lung infections is increasing globally. *Mycobacterium shimoidei* is a slow‐growing NTM that was first isolated in Japan in 1968, gaining species status in 1975 [1](#rcr2428-bib-0001){ref-type="ref"}. Since then, a number of cases of infection have been reported worldwide [1](#rcr2428-bib-0001){ref-type="ref"}, [2](#rcr2428-bib-0002){ref-type="ref"}, [3](#rcr2428-bib-0003){ref-type="ref"}, [4](#rcr2428-bib-0004){ref-type="ref"}, [5](#rcr2428-bib-0005){ref-type="ref"}, [6](#rcr2428-bib-0006){ref-type="ref"}, [7](#rcr2428-bib-0007){ref-type="ref"}.

Case Report {#rcr2428-sec-0002}
===========

A 61‐year‐old man from Okinawa, Japan, presented at his local hospital complaining of cough and bloody sputum during the preceding week. He was a current smoker with a history of chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis that had been treated with prednisolone 7.5 mg per day and methotrexate 12 mg per day since 2005 by a primary care physician. He was a professional gardener. Chest X‐ray demonstrated a thin‐walled cavitary lesion in the upper right lobe. He was referred to our hospital for further evaluation. Chest computed tomography (CT) on the first visit showed a large, thin‐walled cavitary lesion, pleural wall thickening, trabecular and linear shadows in the upper right lobe, and bronchiectasis in the upper and middle lobe (Fig. [1](#rcr2428-fig-0001){ref-type="fig"}A--C). Acid‐fast bacilli were found on Ziehl--Neelsen staining of two separate sputum smears, respiratory specimens were cultured with 2% Ogawa agar, and the resulting bacterial colonies were collected for species identification. Polymerase chain reaction for tuberculosis (TB) was negative. The resulting suspension liquid was tested using a DNA--DNA hybridization (DDH) method from a commercially available identification kit (Kyokuto Pharmaceutical Industrial Co. Ltd., Tokyo, Japan). Finally, an NTM was isolated from two separate expectorated sputum samples by DDH, which failed to identify the NTM species. The patient\'s haemoptysis symptoms improved spontaneously without treatment, and he was discharged from the hospital on his own judgement. Although we encouraged him to attend regular follow‐ups at the outpatient centre of our hospital, he declined due to personal reasons.

![The chest X‐ray on the first visit demonstrated the large cavitary lesion in the right upper lung fields (A). The thoracic computed tomography showed the large, thin‐wall cavity lesion, the thickness of pleural wall, trabecular and linear shadows in the upper right lobe, and bronchiectasis in the upper and middle lobe (B, C). Six months after treatment, the cavitary lesion and trabecular shadows were decreased (D, E).](RCR2-7-e00428-g001){#rcr2428-fig-0001}

Two years later, in December 2017, the patient was readmitted to our hospital with a recurrence of bloody sputum. The CT scan showed that the cavity in the upper right lobe had extended and the cavity wall had become thinner compared to the previous lesions. Microbiological work‐up again isolated an NTM from two separate expectorated sputum samples, and DDH again failed to identify the bacterial species. The positive cultures were sent to a specialized microbiology laboratory for matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry (MALDI‐TOF MS), and *M. shimoidei* was finally identified. The activities of antimicrobial agents were examined by a commercially available drug susceptibility kit for NTM (Kyokuto Pharmaceutical Industrial Co. Ltd., Tokyo, Japan), with the breakpoints derived using *Mycobacterium kansasii* as a reference*. M. shimoidei* proved susceptible to clarithromycin (CAM), ethambutol (EB), streptomycin, amikacin, and levofloxacin (LVFX); and resistant to rifampicin (RFP). After referring to published literature and the advice of an expert on acid‐fast bacteria, the patient was started on a treatment regimen of CAM, EB, and LVFX in January 2018. His haemoptysis decreased gradually and the cavitary lesion improved (Fig. [1](#rcr2428-fig-0001){ref-type="fig"}D, E). Six months after treatment, acid‐fast culture of sputum was negative.

Discussion {#rcr2428-sec-0003}
==========

The purpose of this study is to communicate the potential utility of MALDI‐TOF MS for identification of *M. shimoidei* that is not identifiable by DDH. This is essential for choice of the appropriate antimicrobial treatment. Notably, this is also the first identification of *M. shimoidei* in Okinawa, the southernmost and only prefecture categorized as subtropical in Japan. Species isolated from patients with NTM lung disease are geographically diverse, although the *Mycobacterium avium* complex is the commonest species in most countries, including mainland Japan [8](#rcr2428-bib-0008){ref-type="ref"}. Recently, our group reported that Okinawa may be one of the few places where the *Mycobacterium abscessus* complex is the predominant pathogen causing NTM lung disease [9](#rcr2428-bib-0009){ref-type="ref"}.

Previously published details of 25 cases and this case are summarized together in Table [1](#rcr2428-tbl-0001){ref-type="table"} [1](#rcr2428-bib-0001){ref-type="ref"}, [2](#rcr2428-bib-0002){ref-type="ref"}, [3](#rcr2428-bib-0003){ref-type="ref"}, [4](#rcr2428-bib-0004){ref-type="ref"}, [5](#rcr2428-bib-0005){ref-type="ref"}, [6](#rcr2428-bib-0006){ref-type="ref"}, [7](#rcr2428-bib-0007){ref-type="ref"}, which is based on the format of the table in the study by Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"} Cases with normal chest X‐ray were excluded in Table [1](#rcr2428-tbl-0001){ref-type="table"}. Previous reports of *M. shimoidei* infections have been predominantly in the lungs, and largely among male patients. The most commonly associated concurrent conditions were COPD, bronchiectasis, and past TB [1](#rcr2428-bib-0001){ref-type="ref"}, [2](#rcr2428-bib-0002){ref-type="ref"}, [3](#rcr2428-bib-0003){ref-type="ref"}, [4](#rcr2428-bib-0004){ref-type="ref"}, [5](#rcr2428-bib-0005){ref-type="ref"}, [6](#rcr2428-bib-0006){ref-type="ref"}, [7](#rcr2428-bib-0007){ref-type="ref"}. Common symptoms were cough or sputum production, weight loss, dyspnoea, fevers, or sweats. Radiology demonstrated cavitating disease in approximately 70% of patients (Table [1](#rcr2428-tbl-0001){ref-type="table"}). The infection route for humans is unknown.

###### 

Clinical features, treatments and outcomes of Mycobacterium shimoidei lung infection.

  Age (year)/sex   Identfication methods                         Symptoms/signs                       Other diseases                         Radiology                           Therapy (time)                       Outcome                Reference
  ---------------- --------------------------------------------- ------------------------------------ -------------------------------------- ----------------------------------- ------------------------------------ ---------------------- --------------------------------------------------------------
  56/M             Biochemical identification                    Unknown                              Not reported                           Cavity                              Not reported                         Died of lung disease   Tsukamura et al. [1](#rcr2428-bib-0001){ref-type="ref"}
  68/M             Bergey\'s Manual of Systematic Bacteriology   Sputum                               TB, Addison\'s disease                 Cavity                              INH, SM, RFP, kanamycin (4 months)   Died                   Tortoli and Simonetti [7](#rcr2428-bib-0007){ref-type="ref"}
  56/M             Bergey\'s Manual of Systematic Bacteriology   Sputum                               None                                   Cavity                              Unknown                              Unknown                Tortoli and Simonetti [7](#rcr2428-bib-0007){ref-type="ref"}
  77/M             Bergey\'s Manual of Systematic Bacteriology   Sputum                               Silicosis                              Cavity                              INH, RFP, SM                         Improved               Tortoli and Simonetti [7](#rcr2428-bib-0007){ref-type="ref"}
  53/F             Genetic assay (16S rRNA)                      Fatigue, weight loss                 oesophagus cancer                      Cavity                              INH, RFP, PZA, EB                    Died                   Mayall et al. [4](#rcr2428-bib-0004){ref-type="ref"} 1999
  68/M             Genetic assays (16S rRNA)                     Cough, fever, sputum                 TB, gastrc ulcer, pneumothorax, COPD   Consolidation                       RFP, EB, PZA, CAM, CPFX (6 months)   Improved               Takayama et al. [5](#rcr2428-bib-0005){ref-type="ref"} 2006
  45/M             Genetic assay (16S rRNA)                      Haemoptysis                          COPD                                   Cavity, consolidation               INH, RFP (6 months)                  Stable                 Saito et al. [2](#rcr2428-bib-0002){ref-type="ref"}
  75/M             Genetic assay (16S rRNA)                      Cough, fatigue, fever, weight loss   TB                                     Cavity, Consolidation               RFP, EB, SM, CAM (12 months)         Improved               Saito et al. [2](#rcr2428-bib-0002){ref-type="ref"}
  53/F             Genetic assays (16S rRNA, etc.)               Cough, haemoptysis                   TB                                     bronchiectasis                      EB, AMK, RIF, CAM (18 months)        Improved               Nadia et al. 2013 \[13\]
  83/M             Genetic assays (16S rRNA, etc.)               Sputum                               glomerulonephritis                     Cavity, Nodules, pleural thicking   CAM, RFP, EB                         Improved               Kanaji et al. 2013 [6](#rcr2428-bib-0006){ref-type="ref"}
  60/M             Genetic assays (16S rRNA, etc.)               Cough, sputum, weight los            COPD, asthma                           Cavities, nodule                    Observed                             Stable                 Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  56/M             Genetic assays (16S rRNA, etc.)               Unknown                              Unknown                                Unknown                             None                                 Died                   Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  75/F             Genetic assays (16S rRNA, etc.)               Cough, sputum, weight loss           COPD, HF, AF, GERD                     Cavities, nodules                   None                                 Died of other cause    Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  72/M             Genetic assays (16S rRNA, etc.)               Cough, dyspnoea, weight loss         COPD, bronchiectasis, IHD              Cavity, nodules                     Observed                             Died of lung disease   Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  62/M             Genetic assays (16S rRNA, etc.)               Cough, weight loss, night sweats     None                                   Cavity                              INH, RFP, PZA, EB (6 months)         Stable                 Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  68/M             Genetic assays (16S rRNA, etc.)               Cough, haemoptysis, fatigue          COPD, aspergillus, HTN                 Cavities, consolidation             CAM, MFX, SMX (12 months)            Improved               Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  70/M             Genetic assays (16S rRNA, etc.)               Cough, sputum, chest pain            Lung cancer, COPD, bronchiectasis      Cavities                            CAM, RIF, EB (12 months)             Died of lung disease   Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  77/F             Genetic assays (16S rRNA, etc.)               Cough, weight loss, fatigue          COPD, GERD                             Cavity, nodules                     CAM, RFP, EB (18 months)             Improved               Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  68/M             Genetic assays (16S rRNA, etc.)               Cough, sputum, weight loss           COPD, RA, anaemia                      Cavity, consolidation               Observed                             Stable                 Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  76/M             Genetic assays (16S rRNA, etc.)               Dyspnoea, weight loss                COPD, anaemia                          Nodules                             None                                 Unknown                Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  84/M             Genetic assays (16S rRNA, etc.)               Cough, sputum, weight loss           Lung cancer, GERD                      Mass, effusion                      Observed                             Died of lung disease   Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  84/M             Genetic assays (16S rRNA, etc.)               Cough, dyspnoea, fatigue             COPD, bronchiectasis                   Consolidation                       Observed                             Improved               Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  29/M             Genetic assays (16S rRNA, etc.)               Cough, dyspnoea, weight loss         CF, bronchiectasis                     Nodules                             AMK, CFX, AZM, CFZ (24 months)       Improved               Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  74/F             Genetic assays (16S rRNA, etc.)               Cough, sputum                        Bronchiectasis                         Nodules, consolidation              Observed                             Improved               Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  84/F             Genetic assays (16S rRNA, etc.)               Cough, haemoptysis, weight loss      Bronchiectasis, type 2 diabetes, HTN   Nodules                             CAM (2 months)                       Improved               Baird et al. [3](#rcr2428-bib-0003){ref-type="ref"}
  61/M             MALDI‐TOF MS                                  Haemoptysis                          COPD, RA                               Cavity, pleural wall thickening     CAM, EB, LVFX (18 months)            Improved               Nagano 2019 \[this case\]

Abbreviations: AF, atrial fibrillation; AMK, amikacin; AZM, azithrimycin; CAM, clarithromycin; CF, cystic fibrosis; CFX, cefoxitin; CFZ, clofazimine; COPD, chronic obstructive pulmonary disease; CPFX, ciprofloxacin; EB, ethambutol; GERD, gastro esophageal reflux disease; HF, heart failure; HTN, hypertension; IHD, ischemic heart disease; INH, isoniazid; LVFX, levofloxacin; MFX, moxifloxacin; PZA, pyrazinamide; RA, rheumatoid arthritis; RFP, rifampicin; SM, streptomycin; SMX, sulfamethoxazole; TB, tuberculosis.

MALDI‐TOF MS is a proteomics method that permits rapid and accurate identification of mycobacterium species from positive cultures [10](#rcr2428-bib-0010){ref-type="ref"}. Whereas only 18 acid‐fast bacteria species have been identified using DDH, MALDI‐TOF MS successfully identified 148 species from NTM isolates [10](#rcr2428-bib-0010){ref-type="ref"}. Furthermore, compared to other molecular techniques, MALDI‐TOF MS is more cost effective, provides faster identification of mycobacterial isolates to the species level, and often facilitates earlier implementation of more appropriate therapies than is possible with previous bacterial identification methods [10](#rcr2428-bib-0010){ref-type="ref"}, [11](#rcr2428-bib-0011){ref-type="ref"}.

Although more information about drug susceptibilities of *M. shimoidei* is required, it is known to be resistant to isoniazid and RFP, and susceptible to EB and rifabutin (RFB) [2](#rcr2428-bib-0002){ref-type="ref"}, [4](#rcr2428-bib-0004){ref-type="ref"}, [5](#rcr2428-bib-0005){ref-type="ref"}. Recently, Baird et al. suggested drug regimens combining RFB, EB, and CAM, with moxifloxacin/LVFX, sulfamethoxazole, pyrazinamide, and clofazimine also being potentially useful [3](#rcr2428-bib-0003){ref-type="ref"}. In the case presented here, susceptibility testing combined with expert opinion permitted to add LVFX to the treatment regimen for *M. shimoidei*. Increased recognition and understanding of this pathogen are necessary to expedite diagnosis and improve patient outcomes.
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